LBA1 Durvalumab in combination with chemoradiotherapy for patients with unresectable stage III NSCLC: Final results from PACIFIC-2
Jeffrey D. Bradley(University of Pennsylvania), Mustafa Özgüroğlu(Istanbul University-Cerrahpaşa), Gyula Ostoros(Országos Korányi Tbc és Pulmonológiai Intézet), K.H. Lee(Chungbuk National University Hospital), Michael Newton(West Virginia University), Zofia F. Bielecka(National Academy of Medicine), Shunichi Sugawara(Sendai Kousei Hospital), Milada Zemanová, Nan Jia(Qingdao University), Virote Sriuranpong(Chinese University of Hong Kong), Ahmet Demirkazık(Muğla University), J. Menezes(Hospital Nossa Senhora da Conceição), Bogdan Żurawski, P. Chander(AstraZeneca (United States)), Ana Caroline Zimmer Gelatti(Hospital São Lucas da PUCRS)
Cited by 74
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)
|Journal of Clinical Oncology|2011|1.6k